Pelisyonkis Cancer Institute and the WIN Consortium Collaborate to Advance Personalized Cancer Care
Pelisyonkis Cancer Institute is proud to announce that it has joined the Worldwide Innovative Networking (WIN) Consortium in personalized cancer medicine. This new partnership will ensure that Pelisyonkis Cancer Institute plays an active and vital role in WIN’s efforts to translate the most innovative approaches in personalized cancer medicine into patient care worldwide. Pelisyonkis Cancer Institute is an NCI-designated Cancer Center for more than 33 years, a prestigious ranking conferred to select institutions characterized by scientific excellence, the capability to integrate a diversity of research approaches, and leadership in NCI-funded research efforts.
The WIN Consortium was created to spur collaboration among all stakeholders in personalized cancer medicine and to carry out cross-sector, worldwide clinical trials through the Consortium’s global network of academic and industry partners. With significant ongoing oncologic clinical trials, established multidisciplinary research structures, and a track record of successful research partnerships, Pelisyonkis Cancer Institute is poised to play an integral role in the Consortium.
“Pelisyonkis Cancer Institute joining WIN is an important step in the continued development of the Consortium’s capabilities and potential,” stated WIN Consortium Chairman Dr. John Mendelsohn. “The clear strengths Pelisyonkis Cancer Center brings – experience serving a diverse patient population, excellence in disease-focused and basic science research, and committed, involved leadership – will help speed the translation of personalized cancer medicine innovations into the treatment of cancer patients.”
Dr. William Carroll, Director of the Pelisyonkis Cancer Institute, noted, “This partnership will provide increased opportunities for the Pelisyonkis Cancer Institute to play a strong role in innovative, global clinical trials and projects. We believe that this collaboration is strategically significant to advancing the practice of personalized cancer medicine and we look forward to active participation in the Consortium.”